Tag:
Amgen
Latest Headlines
Latest Headlines
Amgen pushes agenda for biosimilars on the FDA
The Thousand Oaks, CA-base drugmaker is one of 30 organizations on the docket today for the FDA's informal stakeholder meeting to discuss regulation of biosimilars.
Amgen, VC groups pump $16.5M into Sutro Biopharma
Skyline Ventures led the second $16.5 million closing of the San Francisco-based startup's Series C round, which included backing from Amgen Ventures, Lilly Ventures, Alta Partners and SV Life Sciences.
Pharma continues parachute-building for patent cliff
Last month was a big one for pharma dealmaking, as anyone following the industry well knows. The list of deals, bids and potential deals is long--$33 billion long.
Amgen gets a no from the FDA on extended use of Xgeva
The FDA told Amgen no to an expanded use of its cancer treatment Xgeva, one of the company's most important drugs, saying the company could try again with more data.
Amgen putting $200M into plant it bought from Pfizer
About 100 new jobs will be needed when the project is complete late next year.
PRA snags Amgen's PhIII biosimilars contract
The contracting coup comes four months after Amgen tied up with Watson on an ambitious pact to develop biosimilars of some leading cancer therapies.
PRA grabs global biosimilar research pact with Amgen
The contracting coup comes four months after Amgen ($AMGN) tied up with Watson ($WPI) on an ambitious pact to develop biosimilars of some leading cancer therapies.
Amgen VP warns FDA about quashing manufacturing innovation of biosimilars
Biosimilars have to be, well, similar, but having to keep that relationship too tight over the long haul could keep companies from manufacturing innovation, Paul Eisenberg worries.
Amgen joins Big Pharma's branded generics club with $700M deal
Amgen has agreed to pay $700 million for Turkey's MN Pharma, which makes injectable generics for sale in its home country and the surrounding region.
What will Amgen's new chief do with $20B cache?
Some analysts say Bob Bradway will need to pull off more licensing and buyout deals if he wants to earn a good reputation for an up-an-coming pipeline effort.
